📣 VC round data is live. Check it out!
- Public Comps
- IBA Group
IBA Group Valuation Multiples
Discover IBA Group's revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like MiMedx Group, Cerus, Cytek Biosciences, Polynovo and more.
IBA Group Overview
About IBA Group
Ion Beam Applications SA develops and manufactures medical devices and software solutions. The firm operates in two segments: proton therapy and other accelerators and dosimetry. Proton therapy and other accelerators business contribute to the majority of sales. It offers solutions for precision cancer treatment through the use of proton beams, as well as cyclotrons used for the production of radioisotopes and industrial accelerators for sterilization and ionization. The dosimetry business sells measurement and quality assurance instruments for radiotherapy and medical imaging. The firm operates in three geographical areas: Belgium, the United States, and the Rest of the World.
Founded
1986
HQ

Employees
2.1K
Website
Financials (LTM)
EV
$594M
Valuation Multiples
Start free trialIBA Group Financials
IBA Group reported last 12-month revenue of $724M and EBITDA of $55M.
In the same LTM period, IBA Group generated $55M in EBITDA and $19M in net income.
Revenue (LTM)
IBA Group P&L
In the most recent fiscal year, IBA Group reported revenue of $722M and EBITDA of $52M.
IBA Group is profitable as of last fiscal year, with gross margin of 32%, EBITDA margin of 7%, and net margin of 2%.
Financial data powered by Morningstar, Inc.
IBA Group Stock Performance
IBA Group has current market cap of $534M, and enterprise value of $594M.
Market Cap Evolution
IBA Group's stock price is $18.34.
IBA Group share price increased by 39.2% in the last year.
IBA Group has an EPS (earnings per share) of $0.51.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $594M | $534M | 0.1% | 0.0% | 19.6% | 39.2% | $0.51 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialIBA Group Valuation Multiples
IBA Group trades at 0.8x EV/Revenue multiple, and 10.8x EV/EBITDA.
EV / Revenue (LTM)
IBA Group Financial Valuation Multiples
As of June 3, 2026, IBA Group has market cap of $534M and EV of $594M.
IBA Group has a P/E ratio of 27.8x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified IBA Group Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


IBA Group Margins & Growth Rates
IBA Group grew revenue by 2% and EBITDA by 13% in the last fiscal year.
In the most recent fiscal year, IBA Group reported gross margin of 32%, EBITDA margin of 7%, and net margin of 2%.
IBA Group Margins
IBA Group Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
IBA Group Operational KPIs
IBA Group's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.
IBA Group's Rule of 40 is 10% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
IBA Group's Rule of X is 14% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
IBA Group Competitors
IBA Group competitors include MiMedx Group, Cerus, Cytek Biosciences, Polynovo, Bioventus, Tactile Medical, Sofwave Medical, NeuroPace, Japan Lifeline and 2seventy bio.
Most IBA Group public comparables operate across Medical Devices, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 0.9x | 1.1x | 3.7x | 6.4x | |||
| 2.4x | 2.3x | 58.8x | 40.6x | |||
| 1.5x | 1.5x | (463.4x) | (186.0x) | |||
| 5.9x | 5.0x | 72.0x | 57.2x | |||
| 1.4x | 1.3x | 6.8x | 6.7x | |||
| 1.4x | 1.4x | 10.6x | 10.1x | |||
| 6.0x | - | 68.7x | - | |||
| 5.7x | 5.7x | (114.3x) | (86.6x) | |||
This data is available for Pro users. Sign up to see all IBA Group competitors and their valuation data. Start Free Trial | ||||||
Acquisitions by IBA Group
IBA Group has acquired 3 companies to date.
Last acquisition by IBA Group was on December 19th 2025. IBA Group acquired Optimized Radiochemical Applications for $22M (EV/Revenue multiple available to Pro users).
Latest Acquisitions by IBA Group
| Description | Optimized Radiochemical Applications produces sterile injectable PET radiopharmaceuticals and supplies automated synthesizers for nuclear medicine imaging. | PhantomX is a Berlin-based supplier of anthropomorphic phantoms for medical imaging validation and AI training. Its models simulate human tissues for CT, MRI, and ultrasound, incorporating contrast agents and lesions. Used by radiology departments at Charité Hospital since 2018, PhantomX supports dosimetry and algorithm certification. | Santa Fe Springs-headquartered Radcal is a provider of radiation dosimetry instruments for X-ray quality assurance in medical imaging facilities. Its product line includes the Accu-Gold dosimeters and RaySafe X2 analyzers used in over 10,000 hospitals globally. Founded in 1985, Radcal calibrates equipment for CT, mammography, and fluoroscopy systems, complying with IEC 61223 standards. |
| HQ Country | |||
| HQ City | - | Berlin | Los Angeles, CA |
| Deal Date | 19 Dec 2025 | 3 Nov 2025 | 9 Feb 2024 |
| Valuation | $22M | undisclosed | $3M |
| EV/Revenue | |||
| EV/EBITDA | |||
This data is available for Pro users. Sign up to see all IBA Group acquisitions and their M&A valuation multiples. Start Free Trial | |||
Investments by IBA Group
IBA Group has invested in 3 companies to date.
Latest investment by IBA Group was on April 28th 2025. IBA Group invested in Signatur Biosciences in their $7M Seed round (EV/Revenue multiple available to Pro users).
Latest Investments by IBA Group
| Description | Signatur Biosciences is a 2022-founded molecular diagnostics company in Oslo developing proteomics-based tests for precision medicine in oncology and infectious diseases across Scandinavia. | PanTera is a Belgian biotech firm producing actinium-225 radioisotopes for alpha-emitting cancer radiopharmaceuticals. The company scales extraction from radium-226 precursors and recycles waste streams for sustainability. Headquartered in Ghent since 2020, PanTera supplies clinical trials for prostate and leukemia treatments through partnerships with European pharma developers. | Jerusalem-headquartered HIL Applied Medical develops ultra-compact proton therapy accelerators through a patented method integrating nanotechnology, ultra-high-intensity lasers, and ultra-fast magnets. This technology shrinks system size, complexity, and costs to deliver single-room treatment solutions. The privately held firm receives backing from venture capital investors and global strategic partners while operating a wholly owned subsidiary in Reno, Nevada. |
| HQ Country | |||
| HQ City | New York City, NY | Mol | Jerusalem |
| Deal Date | 28 Apr 2025 | 11 Sep 2024 | 23 Aug 2016 |
| Round | Seed | Series A | Strategic investment |
| Raised | $7M | $112M | $2M |
| Investors | IBA Group; Noshaq | EQT; Eurazeo; IBA Group; Korys; Kurma Partners; Paladin; PMV; SFPIM | IBA Group |
| Valuation | undisclosed | $313M | undisclosed |
| EV/Revenue | |||
| EV/EBITDA | |||
This data is available for Pro users. Sign up to see all IBA Group investments and their VC round multiples. Start Free Trial | |||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout IBA Group
| When was IBA Group founded? | IBA Group was founded in 1986. |
| Where is IBA Group headquartered? | IBA Group is headquartered in Belgium. |
| How many employees does IBA Group have? | As of today, IBA Group has over 2K employees. |
| Who is the CEO of IBA Group? | IBA Group's CEO is Olivier Legrain. |
| Is IBA Group publicly listed? | Yes, IBA Group is a public company listed on Euronext Brussels. |
| What is the stock symbol of IBA Group? | IBA Group trades under IBAB ticker. |
| When did IBA Group go public? | IBA Group went public in 1998. |
| Who are competitors of IBA Group? | IBA Group main competitors include MiMedx Group, Cerus, Cytek Biosciences, Polynovo, Bioventus, Tactile Medical, Sofwave Medical, NeuroPace, Japan Lifeline, 2seventy bio. |
| What is the current market cap of IBA Group? | IBA Group's current market cap is $534M. |
| What is the current revenue of IBA Group? | IBA Group's last 12 months revenue is $724M. |
| What is the current revenue growth of IBA Group? | IBA Group revenue growth (NTM/LTM) is 2%. |
| What is the current EV/Revenue multiple of IBA Group? | Current revenue multiple of IBA Group is 0.8x. |
| What is the current EBITDA of IBA Group? | IBA Group's last 12 months EBITDA is $55M. |
| What is IBA Group's EBITDA margin? | IBA Group's last 12 months EBITDA margin is 8%. |
| What is the current EV/EBITDA multiple of IBA Group? | Current EBITDA multiple of IBA Group is 10.8x. |
| How many companies IBA Group has acquired to date? | As of June 2026, IBA Group has acquired 3 companies. |
| What was the largest acquisition by IBA Group? | $22M acquisition of Optimized Radiochemical Applications on 19th December 2025 was the largest M&A IBA Group has done to date. |
| What companies IBA Group acquired? | IBA Group acquired Optimized Radiochemical Applications, Radcal, and PhantomX. |
| In how many companies IBA Group has invested to date? | As of June 2026, IBA Group has invested in 3 companies. |
| What was the last IBA Group investment? | On 28th April 2025 IBA Group invested in Signatur Biosciences, participating in a $7M Seed round, alongside Noshaq. |
| In what companies IBA Group invested in? | IBA Group invested in PanTera, Signatur Biosciences, and Hil Applied Medical. |
See public comps similar to IBA Group
Lists including IBA Group
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.



